Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions.

Adult Animals Antitubercular Agents / administration & dosage Biological Availability Drug Therapy, Combination Female Humans Lung / diagnostic imaging Male Mycobacterium tuberculosis / physiology Positron Emission Tomography Computed Tomography Rabbits Rifampin / administration & dosage Tissue Distribution Tuberculosis / diagnosis Tuberculosis, Pulmonary / diagnosis

Journal

Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015

Informations de publication

Date de publication:
04 2020
Historique:
received: 19 08 2019
accepted: 15 01 2020
pubmed: 19 2 2020
medline: 23 7 2020
entrez: 19 2 2020
Statut: ppublish

Résumé

Tuberculosis (TB) is the leading cause of death from a single infectious agent, requiring at least 6 months of multidrug treatment to achieve cure

Identifiants

DOI: 10.1038/s41591-020-0770-2 PMID: 32066976 PMC: PMC7160048
pubmed: 32066976
doi: 10.1038/s41591-020-0770-2
pii: 10.1038/s41591-020-0770-2
pmc: PMC7160048
mid: NIHMS1564768
doi:

Substances chimiques

Antitubercular Agents 0
Rifampin VJT6J7R4TR

Types de publication

Clinical Study Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

529-534

Subventions

Organisme : NIAID NIH HHS
ID : K08 AI139371
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB020539
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL131829
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI145435
Pays : United States

Références

World Health Organization. Global Tuberculosis Report 2019 (World Health Organization, 2019).
Reynolds, J. & Heysell, S. K. Understanding pharmacokinetics to improve tuberculosis treatment outcome. Expert Opin. Drug Metab. Toxicol. 10, 813–823 (2014).
pubmed: 24597717 pmcid: 4112565
DeMarco, V. P. et al. Determination of [
pubmed: 26169396 pmcid: 4538528
Tucker, E. W. et al. Noninvasive
pubmed: 30518610 pmcid: 6360528
Diacon, A. H. et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob. Agents Chemother. 51, 2994–2996 (2007).
pubmed: 17517849 pmcid: 1932511
Chigutsa, E. et al. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob. Agents Chemother. 59, 38–45 (2015).
pubmed: 25313213
Pasipanodya, J. G. et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J. Infect. Dis. 208, 1464–1473 (2013).
pubmed: 23901086 pmcid: 3789573
Swaminathan, S. et al. Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests. Clin. Infect. Dis. 63, S63–S74 (2016).
pubmed: 27742636 pmcid: 5064152
Grobbelaar, M. et al. Evolution of rifampicin treatment for tuberculosis. Infect. Genet. Evol. 74, 103937 (2019).
pubmed: 31247337
Boeree, M. J. et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect. Dis. 17, 39–49 (2017).
pubmed: 28100438 pmcid: 5159618
Svensson, R. J. et al. Greater early bactericidal activity at higher rifampicin doses revealed by modeling and clinical trial simulations. J. Infect. Dis. 218, 991–999 (2018).
pubmed: 29718390
Pasipanodya, J. G. et al. Artificial intelligence-derived 3-way concentration-dependent antagonism of gatifloxacin, pyrazinamide, and rifampicin during treatment of pulmonary tuberculosis. Clin. Infect. Dis. 67, S284–S292 (2018).
pubmed: 30496458 pmcid: 6904294
Ehrlich, P. Address in pathology on chemotherapeutics: scientific principles, methods, and results. Lancet 182, 445–451 (1913).
Velasquez, G. E. et al. Efficacy and safety of high-dose rifampin in pulmonary tuberculosis: a randomized controlled trial. Am. J. Respir. Crit. Care Med. 198, 657–666 (2018).
pubmed: 29954183 pmcid: 6118011
Aarnoutse, R. E. et al. Pharmacokinetics, tolerability, and bacteriological response of rifampin administered at 600, 900, and 1,200 milligrams daily in patients with pulmonary tuberculosis. Antimicrob. Agents Chemother. 61, e01054-17 (2017).
pubmed: 28827417 pmcid: 5655063
Peloquin, C. A. et al. Pharmacokinetic evidence from the HIRIF trial to support increased doses of rifampin for tuberculosis. Antimicrob. Agents Chemother. 61, e01054-17 (2017).
Te Brake, L. H. M., Boeree, M. J. & Aarnoutse, R. E. Conflicting findings on an intermediate dose of rifampicin for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 199, 1166–1167 (2019).
Dorman, S. E. et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the Tuberculosis Trials Consortium. J. Infect. Dis. 206, 1030–1040 (2012).
pubmed: 22850121
Prideaux, B. et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat. Med. 21, 1223–1227 (2015).
pubmed: 26343800 pmcid: 4598290
Dheda, K. et al. Drug-penetration gradients associated with acquired drug resistance in patients with tuberculosis. Am. J. Respir. Crit. Care Med. 198, 1208–1219 (2018).
pubmed: 29877726 pmcid: 6221573
Hunter, R. L. The pathogenesis of tuberculosis: the early infiltrate of post-primary (adult pulmonary) tuberculosis: a distinct disease entity. Front. Immunol. 9, 2108 (2018).
pubmed: 30283448 pmcid: 6156532
Jain, S. K. et al. Tuberculous meningitis: a roadmap for advancing basic and translational research. Nat. Immunol. 19, 521–525 (2018).
pubmed: 29777209 pmcid: 6089350
Pan, H. et al. Ipr1 gene mediates innate immunity to tuberculosis. Nature 434, 767–772 (2005).
pubmed: 15815631 pmcid: 1388092
Nau, R. et al. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J. Antimicrob. Chemother. 29, 719–724 (1992).
pubmed: 1506352
Urbanowski, M. E. et al. Repetitive aerosol exposure promotes cavitary tuberculosis and enables screening for targeted inhibitors of extensive lung destruction. J. Infect. Dis. 218, 53–63 (2018).
pubmed: 29554286 pmcid: 5989619
Canetti, G. Present aspects of bacterial resistance in tuberculosis. Am. Rev. Respir. Dis. 92, 687–703 (1965).
pubmed: 5321145
Benator, D. et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360, 528–534 (2002).
pubmed: 12241657
Kjellsson, M. C. et al. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob. Agents Chemother. 56, 446–457 (2012).
pubmed: 21986820 pmcid: 3256032
Rifat, D. et al. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data. Sci. Transl. Med. 10, eaai7786 (2018).
pubmed: 29618565 pmcid: 5969904
Le Guellec, C., Gaudet, M. L., Lamanetre, S. & Breteau, M. Stability of rifampin in plasma: consequences for therapeutic monitoring and pharmacokinetic studies. Ther. Drug Monit. 19, 669–674 (1997).
pubmed: 9421109
Samara, E. et al. Antibiotic stability over six weeks in aqueous solution at body temperature with and without heat treatment that mimics the curing of bone cement. Bone Joint Res. 6, 296–306 (2017).
pubmed: 28515059 pmcid: 5457644
Magombedze, G. et al. Transformation morphisms and time-to-extinction analysis that map therapy duration from preclinical models to patients with tuberculosis: translating from apples to oranges. Clin. Infect. Dis. 67, S349–S358 (2018).
pubmed: 30496464 pmcid: 6260172
Lappin, G., Noveck, R. & Burt, T. Microdosing and drug development: past, present and future. Expert Opin. Drug Metab. Toxicol. 9, 817–834 (2013).
pubmed: 23550938 pmcid: 4532546
Nix, D. E., Goodwin, S. D., Peloquin, C. A., Rotella, D. L. & Schentag, J. J. Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob. Agents Chemother. 35, 1953–1959 (1991).
pubmed: 1759813 pmcid: 245307
Liu, L. et al. Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons. J. Med. Chem. 53, 2882–2891 (2010).
pubmed: 20205479 pmcid: 2866172
Ordonez, A. A. et al. Molecular imaging of bacterial infections: overcoming the barriers to clinical translation. Sci. Transl. Med. 11, eaax8251 (2019).
pubmed: 31484790
Rubinstein, L. V. et al. The statistics of phase 0 trials. Stat. Med. 29, 1072–1076 (2010).
pubmed: 20419759 pmcid: 3902019
Ordonez, A. A. et al. Radiosynthesis and PET bioimaging of
pubmed: 31345032
US Food and Drug Administration. Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies (US Food and Drug Administration, 2006).
US Food and Drug Administration. Guidance for Industry and Researchers: The Radioactive Drug Research Committee: Human Research Without an Investigational New Drug Application (US Food and Drug Administration, 2010).
US Food and Drug Administration. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers (Center for Drug Evaluation and Research, 2005).
Hedlund, L. W., Vock, P. & Effmann, E. L. Evaluating lung density by computed tomography. Semin. Respir. Crit. Care Med. 5, 76–88 (1983).
Smythe, W. et al. A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. Antimicrob. Agents Chemother. 56, 2091–2098 (2012).
pubmed: 22252827 pmcid: 3318330
Wagner, C. C. & Langer, O. Approaches using molecular imaging technology—use of PET in clinical microdose studies. Adv. Drug Deliv. Rev. 63, 539–546 (2011).
pubmed: 20887762
Svensson, R. J. et al. A population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin doses. Clin. Pharmacol. Ther. 103, 674–683 (2018).
pubmed: 28653479
Acocella, G., Bonollo, L., Mainardi, M., Margaroli, P. & Tenconi, L. Serum and urine concentrations of rifampicin administered by intravenous infusion in man. Arzneimittelforschung 27, 1221–1226 (1977).
pubmed: 578447
Nitti, V., Virgilio, R., Patricolo, M. & Iuliano, A. Pharmacokinetic study of intravenous rifampicin. Chemotherapy 23, 1–6 (1977).
pubmed: 832508
Loos, U. et al. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin. Wochenschr. 63, 1205–1211 (1985).
pubmed: 4087830
Boeree, M. J. et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 191, 1058–1065 (2015).
pubmed: 25654354
Gumbo, T., Pasipanodya, J. G., Romero, K., Hanna, D. & Nuermberger, E. Forecasting accuracy of the hollow fiber model of tuberculosis for clinical therapeutic outcomes. Clin. Infect. Dis. 61 (Suppl. 1), S25–S31 (2015).
pubmed: 26224769

Auteurs

Alvaro A Ordonez (AA)

Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
ORCID: 0000-0002-8571-0655

Hechuan Wang (H)

Center for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, MD, USA.
ORCID: 0000-0002-0792-7816

Gesham Magombedze (G)

Center for Infectious Diseases Research and Experimental Therapeutics, Baylor University Medical Center and Texas Tech University Health Sciences Center, Dallas, TX, USA.

Camilo A Ruiz-Bedoya (CA)

Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Shashikant Srivastava (S)

Center for Infectious Diseases Research and Experimental Therapeutics, Baylor University Medical Center and Texas Tech University Health Sciences Center, Dallas, TX, USA.

Allen Chen (A)

Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Elizabeth W Tucker (EW)

Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
ORCID: 0000-0002-0971-3635

Michael E Urbanowski (ME)

Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Lisa Pieterse (L)

Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

E Fabian Cardozo (E)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
ORCID: 0000-0001-8690-9896

Martin A Lodge (MA)

Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Maunank R Shah (MR)

Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Daniel P Holt (DP)

Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

William B Mathews (WB)

Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Robert F Dannals (RF)

Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Jogarao V S Gobburu (JVS)

Center for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, MD, USA.

Charles A Peloquin (CA)

Infectious Disease Pharmacokinetics Laboratory, Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL, USA.

Steven P Rowe (SP)

Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Tawanda Gumbo (T)

Center for Infectious Diseases Research and Experimental Therapeutics, Baylor University Medical Center and Texas Tech University Health Sciences Center, Dallas, TX, USA.

Vijay D Ivaturi (VD)

Center for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, MD, USA.

Sanjay K Jain (SK)

Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA. sjain5@jhmi.edu.
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA. sjain5@jhmi.edu.
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA. sjain5@jhmi.edu.
Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. sjain5@jhmi.edu.
ORCID: 0000-0001-9620-7070

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Dynamic imaging in patients with tuberculosis...
questionsmedicales.fr › Eucaryotes › Animaux › Dynamic imaging in patients with tuberculosis...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Antituberculeux › Dynamic imaging in patients with tuberculosis...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Pharmacocinétique › Biodisponibilité › Dynamic imaging in patients with tuberculosis...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Dynamic imaging in patients with tuberculosis...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Dynamic imaging in patients with tuberculosis...
questionsmedicales.fr › Appareil respiratoire › Poumon › Dynamic imaging in patients with tuberculosis...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Bâtonnets à Gram positif › Bâtonnets asporogènes à Gram positif › Bâtonnets asporogènes réguliers à Gram positif › Mycobacteriaceae › Mycobacterium › Mycobacterium tuberculosis › Dynamic imaging in patients with tuberculosis...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Tomographie par émission de positons couplée à la tomodensitométrie › Dynamic imaging in patients with tuberculosis...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Lagomorpha › Lapins › Dynamic imaging in patients with tuberculosis...
questionsmedicales.fr › Composés polycycliques › Composés macrocycliques › Lactames macrocycliques › Rifamycine › Rifampicine › Dynamic imaging in patients with tuberculosis...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Pharmacocinétique › Distribution tissulaire › Dynamic imaging in patients with tuberculosis...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à Actinomycetales › Infections à Mycobacterium › Tuberculose › Dynamic imaging in patients with tuberculosis...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Tuberculose pulmonaire › Dynamic imaging in patients with tuberculosis...